About us
A word from our CEO Hanna Sjöström
Our mission is to give preterm born infants a better start in life. By providing neonatal intensive care units (NICUs) with a groundbreaking innovation for continuous lung monitoring that also can provide immediately alert to the personnel of serious health complications, we are upgrading the care that these fragile patients currently receive and filling a unique market gap for pediatric medical devices.
You find our dedicated team at our headquarter in Lund, Sweden, and in Palo Alto, the U.S.
Kind regards,
Hanna Sjöström
CEO, Neola Medical AB
Hanna Sjöström
CEO
Board & Management
Neola Medical’s Board consists of five members elected at Neola Medical’s Annual General Meeting on May 17, 2023.
Märta Lewander Xu
Chairman of the Board since 2019, former CEO on a part-time basis and board member for Neola Medical 2016-2019.
Experience and education
Märta Lewander Xu has a doctorate in technology in physics, has a master’s degree in technical physics and a teaching degree in mathematics and physics. Märta was employed at Gasporox AB (publ) in 2010 as CTO and has been CEO of Gasporox AB (publ) since January 2015, which is listed on Nasdaq First North, board member of Lund Laser Center at Lund University, BeammWave AB, Serstech AB and Inscientia AB, and deputy board member of CxTx AB.
Märta Lewander Xu is independent in relation to the company and its management, independent in relation to the company’s major owners.
Number of shares held in the company
378,496 shares (of which 134,210 in endowment insurance), 60,000 warrants issued within the framework of Incentive program 2021/2025B, 100,000 warrants issued within the framework of Incentive program 2023/2027B.
Anders Weilandt
Board member since 2022.
Experience and education
Anders Weilandt, born 1961, is a Medical Electronics Engineer and holds an Executive MBA from Copenhagen Business School. Anders is the CEO of Chordate Medical AB (publ) and currently has a number of board assignments in various companies. He has previously been President of Ascendia MedTech AB, President of Diabetes Tools Sweden AB and Board member and CEO of Stille AB (publ). Anders has extensive experience of regulatory processes, CE marking and international expansion of new medical devices.
Anders Weilandt is independent in relation to the company and its management, dependent in relation to the company’s major owners.
Number of shares held in the company
0 shares, 300,000 warrants issued within the framework of Incentive program 2023/2027B.
Tommy Hedberg
Board member since 2022.
Experience and education
Tommy Hedberg, born 1955, has a Chemical Engineering degree followed by a post-secondary Economics degree. Tommy also has a medical LIF undergraduate degree from his time at Janssen Pharma. During the years 1998 – 2014 Tommy was CEO at Atos Medical, and 2014–2016 a board member. He was also responsible for marketing and sales at Atos Medical 1990 – 1998. Before Tommy started working at Atos Medical, he worked as head of the medical technology division at Medscand with international marketing and sales. Prior to that, Tommy worked for 9 years in sales and marketing at Janssen Pharma.
Tommy Hedberg is independent in relation to the company and its management, independent in relation to the company’s major owners.
Number of shares held in the company
384,616 shares, 300,000 warrants issued within the framework of Incentive program 2023/2027B.
Mattias Lundin
Board member since 2022.
Experience and education
Mattias Lundin, born 1968, has a degree in Business Administration from IHM Business School in Stockholm and several international strategy and leadership training courses within the Sara Lee Corporation, the Getinge Group and IMD Lausanne. He now works as CEO of Lumito AB (publ) and has previously been Vice President Global Sales at CellaVision AB (publ) and held a number of senior positions within the Arjo Group (formerly Getinge), most recently as Vice President Commercial for International Mature Markets. Mattias has solid international experience in sales and marketing and is a team player with a strong track record when it comes to building successful teams for global expansion of new technology.
Mattias Lundin is independent in relation to the company and its management, independent in relation to the company’s major owners.
Number of shares held in the company
50,000 shares, 300,000 warrants issued within the framework of Incentive program 2023/2027B.
Urban Ottosson
Board member since 2021.
Experience and education
Urban Ottosson has a master’s degree in economics from Lund University and a degree from KTH Executive School in Stockholm. He has worked as CFO since 1999 in several companies, including HEXPOL, Beijer Electronics, Höganäs Group, Öresundskraft and Lammhults Design Group. He is also a private investor in addition to his assignments. Former board member of Lendify AB and chairman of the board of Modity Energy Trading. He was CFO of Neola Medical 2020-2021. He is the CEO and board member of Predictus Asset Management AB.
Urban Ottosson is independent in relation to the company and its management, independent in relation to the company’s major owners.
Number of shares held in the company
468,750 shares, 100,000 warrants issued within the framework of the Incentive program 2021/2025A, 300,000 warrants issued within the framework of Incentive program 2023/2027B.
Neola Medical management & team
Neola Medical’s management consists of CEO Hanna Sjöström and CFO Christian Gyllenberg. In addition to the management, there is a strong team of key people with both technical and medical expertise. The team is also complemented by an extensive network of specialist consultants.
Hanna Sjöström
External CEO since 2019.
Experience and education
Hanna Sjöström holds a Master’s in Business Administration and Technology Management from Lund University in Sweden and an Executive MBA from the Swedish Management Group. Sjöström is a highly commercially focused CEO with proven track record within Fast Moving Consumer Goods for +10 years from international roles at L’Oréal and the Coca-Cola Company in combination with Life Science CEO and executive roles at TePe and Neola Medical AB (publ). Hanna Sjöström is a certified and experienced board member of publicly listed Alteco Medical and privately held AMB Industri AB, Reccan AB and Selcis Biopharma AB.
Number of shares held in the company
303,776 shares, 200,000 warrants issued within the framework of the Incentive program 2021/2025A, 200,000 warrants issued within the framework of Incentive program 2023/2027A.
Christian Gyllenberg
CFO since 2022.
Experience and education
Christian Gyllenberg has a bachelor’s degree in Business Law and a bachelor’s degree in Business Administration from Kristianstad University. He has previously worked with auditing and as a Business Controller in business-related roles at companies in various industries such as EY, Attendo and DHL. He is the CFO of Aurora Punks alongside his assignment at Neola Medical.
Number of shares held in the company
0 shares, 100,000 warrants issued within the framework of Incentive program 2023/2027A.
Sara Bergsten
CTO since 2017.
Experience and education
Sara Bergsten has a PhD in physics from Lunds Tekniska Högskola within laser spectroscopy and optics with a focus on applikations within medical diagnostics and therapy as well as a master’s degree in technical physics. Sara has previous experience in developing MedTech devices for optical diagnostics and therapy from two other smaller companies. She also has nine years experience from a larger industrial company within the aviation industry, ADB Safegate, where she worked with product development and global product owner. Sara is also a board member for Lund Medical Laser Center, LUMLAC.
Number of shares held in the company
145,843 shares, 200,000 warrants issued within the framework of Incentive program 2023/2027A.
Magnus Johnsson
Director Quality Assurance & Regulatory Affairs since 2022.
Experience and education
Magnus Johnsson has a master’s degree in chemical engineering and a bachelor’s degree in systems analysis from Lund University. He has over 20 years of experience from working with quality control within the field of medical technology. Magnus last position was as Director of Quality at CellaVision AB.
Number of shares held in the company
24,000 shares, 100,000 warrants issued within the framework of Incentive program 2023/2027A.
Addressing a critical medical need
Every year almost 15 million children are born preterm (before 37 weeks of pregnancy). Many of them require intensive care. Many people know someone who was born preterm or has been affected by a preterm birth, but fewer understand the risks that arise from it. One of many challenges preterm born infants face is underdeveloped lungs that are unable to provide oxygen to the blood, resulting in a life-threatening condition that, if survived, can lead to complications later on in life.
Neola Medical’s technological innovation Neola® can help healthcare personnel make more informed decisions based on real-time information. Neola Medical’s proven technology uses laser spectroscopy to continuously measure lung volume changes and oxygen gas concentration in preterm infants. This is a safe and non-invasive method to monitor the lungs of these vulnerable patients in real time, thereby provide the possibility of instant treatment of life-threatening conditions and decreasing the risk of disabilities later in life.
Neola® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants.
Building on a historic Swedish legacy of medical technology innovation
Sweden has made invaluable contributions to global healthcare, specifically in neonatal intensive care. As a result, the survival rate of preterm born infants has increased to almost 90 percent. Such was not the case in the 1970s, when modern neonatal care was first introduced. At that time, the mortality rate of children weighing under one kilo was over 90 percent. Since then, Sweden has helped develop world class neonatal intensive care, built on a foundation of the latest technology and nurturing methods that involve parents as well.
Following in the footsteps of diagnostic ultrasound, which was developed in Lund, Sweden in the 1950’s, Lund-based medical technology innovation once again has the potential to revolutionize health care the world over.
Neola Medical Headquarters
Founded in 2016 and headquartered in Lund, Sweden, Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. Neola Medical’s employees, management and board have a wide-ranging, specific and very competitive knowledge of product development, user needs and commercialization of medical technology, making the company well-positioned to take Neola® to market.
For Investors
We are on a journey to revolutionize neonatal intensive care
Learn more about investing in Neola Medical